Alert detail

LCD L36125: MolDX: Breast Cancer Assay: Prosigna® — Palmetto GBA

Policy ID: LCD-L36125Specialty: OncologyAdded: 9/12/2026Effective: April 22, 2021lcd
Low

What changed

Prosigna® breast cancer genomic assay coverage—MolDX rules apply.

Who’s affected: Oncology billing teams · Effective: April 22, 2021

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 7 billing codes.

The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.